Drug Name: Bimzelx
Active Ingredient: bimekizumab
Indication: To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Approval Date: 10/17/2023
Company: UCB, Inc
More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761151s000lbl.pdf